＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity (Q64279107)

12 December 2020

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

12 December 2020

Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors

1 reference

12 December 2020

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1 reference

12 December 2020

Human tumor antigens recognized by T-cells

1 reference

12 December 2020

Prevention of allogeneic fetal rejection by tryptophan catabolism

1 reference

12 December 2020

Effects of complementarity determining region mutations on the affinity of an alpha/beta T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing

1 reference

12 December 2020

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma

1 reference

12 December 2020

Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity

1 reference

12 December 2020

Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

1 reference

12 December 2020

Cbl-b regulates the CD28 dependence of T-cell activation.

1 reference

12 December 2020

X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy

1 reference

12 December 2020

The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3

1 reference

12 December 2020

Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse

1 reference

12 December 2020

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

12 December 2020

Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide

1 reference

12 December 2020

Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells.

1 reference

12 December 2020

Generation of CD4(+)CD25(+) regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression

1 reference

12 December 2020

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

12 December 2020

Origin of regulatory T cells with known specificity for antigen

1 reference

12 December 2020

Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design.

1 reference

12 December 2020

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

12 December 2020

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

12 December 2020

An essential role for Scurfin in CD4+CD25+ T regulatory cells

1 reference

12 December 2020

Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance.

1 reference

12 December 2020

Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance

1 reference

12 December 2020

The cancer/testis genes: review, standardization, and commentary.

1 reference

12 December 2020

Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses

1 reference

12 December 2020

SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation

1 reference

12 December 2020

Immune recognition of self in immunity against cancer

1 reference

12 December 2020

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta

1 reference

12 December 2020

Role of LAG-3 in regulatory T cells.

1 reference

12 December 2020

Number of T reg cells that differentiate does not increase upon encounter of agonist ligand on thymic epithelial cells.

1 reference

12 December 2020

Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells

1 reference

12 December 2020

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression

1 reference

12 December 2020

Activation of human cancer/testis antigen gene, XAGE-1, in tumor cells is correlated with CpG island hypomethylation

1 reference

12 December 2020

CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients

1 reference

12 December 2020

Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire

1 reference

12 December 2020

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

1 reference

12 December 2020

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

12 December 2020

Human T cell responses against melanoma

1 reference

12 December 2020

NY-ESO-1: review of an immunogenic tumor antigen

1 reference

12 December 2020

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

1 reference

12 December 2020

Concise review: cancer/testis antigens, stem cells, and cancer.

1 reference

12 December 2020

Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression

1 reference

12 December 2020

Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3.

1 reference

12 December 2020

Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype

1 reference

12 December 2020

CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity

1 reference

12 December 2020

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis

1 reference

12 December 2020

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

1 reference

12 December 2020

Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

1 reference

12 December 2020

The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.

1 reference

12 December 2020

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

12 December 2020

Antigen presentation in the thymus for positive selection and central tolerance induction

1 reference

12 December 2020

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

1 reference

12 December 2020

LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites

1 reference

12 December 2020

Regulatory T cells in tumor immunity

1 reference

12 December 2020

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

12 December 2020

FOXP3+ regulatory T cells in the human immune system

1 reference

12 December 2020

K33-linked polyubiquitination of T cell receptor-zeta regulates proteolysis-independent T cell signaling

1 reference

12 December 2020

Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-β pathway

1 reference

12 December 2020

The CD4-like molecule LAG-3, biology and therapeutic applications

1 reference

12 December 2020

Cancer/Testis antigen expression on mesenchymal stem cells isolated from different tissues

1 reference

12 December 2020

Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling

1 reference

12 December 2020

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

1 reference

12 December 2020

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

1 reference

12 December 2020

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.

1 reference

12 December 2020

The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

1 reference

12 December 2020

Science gone translational: the OX40 agonist story

1 reference

12 December 2020

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses

1 reference

12 December 2020

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study

1 reference

12 December 2020

Regulatory T cells: mechanisms of differentiation and function

1 reference

12 December 2020

Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma

1 reference

12 December 2020

The role of interleukin-2 during homeostasis and activation of the immune system

1 reference

12 December 2020

The TIGIT/CD226 axis regulates human T cell function

1 reference

12 December 2020

Generation of induced regulatory T cells from primary human naïve and memory T cells

1 reference

12 December 2020

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

1 reference

12 December 2020

Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene

1 reference

12 December 2020

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

1 reference

12 December 2020

Natural and induced T regulatory cells in cancer.

1 reference

12 December 2020

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

1 reference

12 December 2020

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

1 reference

12 December 2020

Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis.

1 reference

12 December 2020

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

1 reference

12 December 2020

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

1 reference

12 December 2020

Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy

1 reference

12 December 2020

Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.

1 reference

12 December 2020

A special population of regulatory T cells potentiates muscle repair

1 reference

12 December 2020

Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy

1 reference

12 December 2020

Regulatory T cells in cancer immunotherapy

1 reference

12 December 2020

Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells

1 reference

12 December 2020

Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses

1 reference

12 December 2020

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

1 reference

12 December 2020

Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells

1 reference

12 December 2020

Concurrent interaction of DCs with CD4(+) and CD8(+) T cells improves secondary CTL expansion: It takes three to tango.

1 reference

12 December 2020

Cancer/testis antigens trigger epithelial-mesenchymal transition and genesis of cancer stem-like cells

1 reference

12 December 2020

Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals

1 reference

12 December 2020

Clinical blockade of PD1 and LAG3--potential mechanisms of action

1 reference

12 December 2020

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response

1 reference

12 December 2020

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

1 reference

12 December 2020

Neoantigens in cancer immunotherapy.

1 reference

12 December 2020

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

12 December 2020

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

1 reference

12 December 2020

Therapeutic cancer vaccines

1 reference

12 December 2020

Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients.

1 reference

12 December 2020

Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.

1 reference

12 December 2020

IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1.

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8(+) T cell responses

1 reference

12 December 2020

TIGIT predominantly regulates the immune response via regulatory T cells.

1 reference

12 December 2020

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

1 reference

12 December 2020

Immune responses to human cancer stem-like cells/cancer-initiating cells

1 reference

12 December 2020

Rationale for anti-OX40 cancer immunotherapy

1 reference

12 December 2020

Targeting the indoleamine 2,3-dioxygenase pathway in cancer

1 reference

12 December 2020

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy

1 reference

12 December 2020

Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers

1 reference

12 December 2020

Roles of regulatory T cells in cancer immunity

1 reference

12 December 2020

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

1 reference

12 December 2020

Peptide vaccination therapy: Towards the next generation

1 reference

12 December 2020

Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers

1 reference

12 December 2020

Next generation predictive biomarkers for immune checkpoint inhibition

1 reference

12 December 2020

The chronic myeloid leukemia stem cell: stemming the tide of persistence

1 reference

12 December 2020

Identification and functional analysis of variants of a cancer/testis antigen LEMD1 in colorectal cancer stem-like cells

1 reference

12 December 2020

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy

1 reference

12 December 2020

T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

1 reference

12 December 2020

Interleukin 4 promotes the development of ex-Foxp3 Th2 cells during immunity to intestinal helminths

1 reference

12 December 2020

PD-1 and CTLA4: Two checkpoints, one pathway?

1 reference

12 December 2020

Regulatory T cells, as a target in anticancer immunotherapy.

1 reference

12 December 2020

An immunogenic personal neoantigen vaccine for patients with melanoma

1 reference

12 December 2020

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

1 reference

12 December 2020

Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer

1 reference

12 December 2020

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

1 reference

12 December 2020

PD1 signal transduction pathways in T cells.

1 reference

12 December 2020

1 reference

12 December 2020

Targeting immunosuppressive adenosine in cancer

1 reference

12 December 2020

Identification and characterization of T reg-like cells in zebrafish

1 reference

12 December 2020

Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor.

1 reference

12 December 2020

Suppression from beyond the grave

1 reference

12 December 2020

Maternal IgG immune complexes induce food allergen-specific tolerance in offspring.

1 reference

12 December 2020

Tregs: Where We Are and What Comes Next?

1 reference

12 December 2020

The antigen ASB4 on cancer stem cells serves as a target for CTL immunotherapy of colorectal cancer

1 reference

12 December 2020

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.

1 reference

12 December 2020

Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.

1 reference

12 December 2020

Next generation of immune checkpoint therapy in cancer: new developments and challenges.

1 reference

12 December 2020

Melanoma and Immune Checkpoint Inhibitors

1 reference

12 December 2020

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

1 reference

12 December 2020